Sabrina M Ebinger1, René Warschkow1,2, Ignazio Tarantino3, Bruno M Schmied1, Ulrich Güller4, Marc Schiesser5. 1. Department of Surgery, Cantonal Hospital of St. Gallen, 9007, St Gallen, Switzerland. 2. Institute of Medical Biometry and Informatics, University of Heidelberg, 69120, Heidelberg, Germany. 3. Department of Surgery, University of Heidelberg, 69120, Heidelberg, Germany. 4. Department of Medical Oncology and Haematology, Cantonal Hospital of St Gallen, 9007, St Gallen, Switzerland. 5. Department of Surgery, Cantonal Hospital of St. Gallen, 9007, St Gallen, Switzerland. marc.schiesser@kssg.ch.
Abstract
BACKGROUND: An increasing fraction of gastric cancer patients present with distant metastases at diagnosis. The objective of the present 11-year population-based trend analysis was to assess the survival rates in patients who underwent and in patients who did not undergo palliative gastrectomy. METHODS: Patients with metastatic gastric cancer were identified from the Surveillance, Epidemiology, and End Results (SEER) database between 1998 and 2009. Time trend and impact of palliative gastrectomy on survival were assessed by both a multivariate Cox proportional hazards model and propensity score matching. RESULTS: We identified 8249 patients with stage IV gastric cancer. The rate of metastatic disease increased from 31.0 % in 1998 to 37.5 % in 2009 (P < 0.001). The palliative gastrectomy rate dropped from 18.8 to 10.2 % (P = 0.004). The median survival for patients who underwent palliative gastrectomy (N = 1445, 17.4 %) and for patients who did not undergo palliative gastrectomy (N = 6804, 82.4 %) was 7 and 3 months, respectively. There was an increase in median overall survival from 2 months (1998) to 3 months (2009) in the no-gastrectomy group, and from 6.5 to 8 months in the gastrectomy group. The 3-year cancer-specific survival rates were 2.1 % (95 % confidence interval 1.7-2.5 %) for patients who did not undergo palliative gastrectomy and 9.4 % (95 % confidence interval 7.8-11.2 %) for patients who underwent palliative gastrectomy (P < 0.001). Palliative gastrectomy was associated with an increased cancer-specific survival in propensity-score-adjusted Cox regression analyses (hazard ratio 0.50, 95 % confidence interval 0.46-0.55, P < 0.001). CONCLUSION: On a population-based level, only modest improvements in prognosis for metastatic gastric cancer were observed in patients who underwent and in patients who did not undergo palliative gastrectomy. Considering the low rate of midterm survivors in both groups, only a small subgroup of patients benefits from palliative gastrectomy.
BACKGROUND: An increasing fraction of gastric cancerpatients present with distant metastases at diagnosis. The objective of the present 11-year population-based trend analysis was to assess the survival rates in patients who underwent and in patients who did not undergo palliative gastrectomy. METHODS:Patients with metastatic gastric cancer were identified from the Surveillance, Epidemiology, and End Results (SEER) database between 1998 and 2009. Time trend and impact of palliative gastrectomy on survival were assessed by both a multivariate Cox proportional hazards model and propensity score matching. RESULTS: We identified 8249 patients with stage IV gastric cancer. The rate of metastatic disease increased from 31.0 % in 1998 to 37.5 % in 2009 (P < 0.001). The palliative gastrectomy rate dropped from 18.8 to 10.2 % (P = 0.004). The median survival for patients who underwent palliative gastrectomy (N = 1445, 17.4 %) and for patients who did not undergo palliative gastrectomy (N = 6804, 82.4 %) was 7 and 3 months, respectively. There was an increase in median overall survival from 2 months (1998) to 3 months (2009) in the no-gastrectomy group, and from 6.5 to 8 months in the gastrectomy group. The 3-year cancer-specific survival rates were 2.1 % (95 % confidence interval 1.7-2.5 %) for patients who did not undergo palliative gastrectomy and 9.4 % (95 % confidence interval 7.8-11.2 %) for patients who underwent palliative gastrectomy (P < 0.001). Palliative gastrectomy was associated with an increased cancer-specific survival in propensity-score-adjusted Cox regression analyses (hazard ratio 0.50, 95 % confidence interval 0.46-0.55, P < 0.001). CONCLUSION: On a population-based level, only modest improvements in prognosis for metastatic gastric cancer were observed in patients who underwent and in patients who did not undergo palliative gastrectomy. Considering the low rate of midterm survivors in both groups, only a small subgroup of patients benefits from palliative gastrectomy.
Entities:
Keywords:
Cancer specific survival; Metastatic gastric cancer; Palliative gastrectomy; Relative survival; Surveillance, Epidemiology, and End Results Program
Authors: A E Dassen; V E P P Lemmens; L V van de Poll-Franse; G J Creemers; S J Brenninkmeijer; D J Lips; A A M Vd Wurff; K Bosscha; J W W Coebergh Journal: Eur J Cancer Date: 2010-03-08 Impact factor: 9.162
Authors: Jillian K Smith; Joshua S Hill; Sing Chau Ng; Theodore P McDade; Shimul A Shah; Jennifer F Tseng Journal: J Gastrointest Surg Date: 2010-09-09 Impact factor: 3.452
Authors: René Warschkow; Matthias Baechtold; Kenneth Leung; Bruno M Schmied; Daniel P Nussbaum; Beat Gloor; Dan G Blazer Iii; Mathias Worni Journal: Gastric Cancer Date: 2017-06-23 Impact factor: 7.370